Edgar Filing: GILEAD SCIENCES INC - Form 4

GILEAD S Form 4 October 03	CIENCES INC											
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549									OMB Number:	3235-0287		
if no lo	this box nger								Expires:	January 31, 2005		
subject Section	to SIAIE 16.	MENT OF	OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES						Estimated as burden hour	verage s per		
Form 4 or Form 5 obligations may continue.response0.5See Instruction 1(b).Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 19400.5												
(Print or Type	e Responses)											
Alton Gregg H Symbol					r Name and Ticker or Trading 5. Relationship Issuer					f Reporting Person(s) to		
(Last)	(First)	(Middle)			Transactior	-	1	(Check	all applicable))		
				Day/Year)				Director 10% Owner X Officer (give title Other (specify				
GILEAD S	SCIENCES, INC., E DRIVE	, 333	10/01/	2014				elow)	below)			
LiniLond			4 10 4	1 (1			C		p & Med Affa			
	(Street)								Individual or Joint/Group Filing(Check plicable Line)			
FOSTER (CITY, CA 94404			·			_	K_Form filed by Or Form filed by Mo erson				
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned												
1.Title of Security (Instr. 3)	(Month/Day/Year) Execution Date, if any			3. 4. Securities Acquired (A) or TransactiorDisposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						(A) or		Transaction(s) (Instr. 3 and 4)	(Instr. 4)			
Common				Code V		(D)	Price					
Stock	10/01/2014			М	31,000	А	\$ 23.755	153,694	D			
Common Stock	10/01/2014			S	25,405	D	\$ 105.8341 (3)	128,289	D			
Common Stock	10/01/2014			S	5,395	D	\$ 106.588 (4)	3 122,894	D			
Common Stock	10/01/2014			S	200	D	\$ 107.465 (5)	122,694	D			
Common Stock	10/01/2014			S	1,751	D	\$ 105.9067	120,943	D			

Edgar Filing: GILEAD SCIENCES INC - Form 4

					(6)		
Common Stock	10/01/2014	S	249	D	\$ 106.6894 (7)	120,694	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of onDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day/	ate	7. Title and A Underlying S (Instr. 3 and 4	Securit
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amo or Num of Sł
Non-Qualified Stock Option (right to buy)	\$ 23.755	10/01/2014		M <u>(1)</u>	31,000	(2)	01/28/2020	Common Stock	31,

Reporting Owners

Reporting Owner Name / Address	Relationships					
1	Director	10% Owner	Officer	Other		
Alton Gregg H GILEAD SCIENCES, INC. 333 LAKESIDE DRIVE FOSTER CITY, CA 94404			EVP, Corp & Med Affairs			
Signatures						
/s/ Marissa Song by Power of A Alton	Attorney f	for Gregg H.	10/03/2014			

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.

Edgar Filing: GILEAD SCIENCES INC - Form 4

- (2) The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- (3) Sale prices reported for the transactions reported here range from \$105.33 to \$106.3291. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (4) Sale prices reported for the transactions reported here range from \$106.33 to \$107.29. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (5) Sale prices reported for the transactions reported here range from \$107.43 to \$107.50. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (6) Sale prices reported for the transactions reported here range from \$105.39 to \$106.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- (7) Sale prices reported for the transactions reported here range from \$106.40 to \$106.90. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.